PLEKHG3: A GPCR Target with Potential as A Drug (G26030)

Target Name: PLEKHG3

NCBI ID: G26030

PLEKHG3

Other Name(s): ARHGEF43 | pleckstrin homology domain containing, family G, member 3 | KIAA0599 | pleckstrin homology and RhoGEF domain containing G3 | Pleckstrin homology domain containing, family G, member 3 | Hj03796 | PH domain-containing family G member 3 | Pleckstrin homology domain containing, family G (with RhoGef domain) member 3 | pleckstrin homology domain containing, family G (with RhoGef domain) member 3 | Pleckstrin homology domain-containing family G member 3 | PKHG3_HUMAN

PLEKHG3: A GPCR Target with Potential as A Drug

PLEKHG3 (ARHGEF43) is a protein that is expressed in various tissues of the body, including the brain, heart, and kidneys. It is a member of the G-protein-coupled receptor (GPCR) family, which is a large superfamily of transmembrane proteins that play a critical role in cellular signaling.

Plekhhg3 is a 19kDa protein that is expressed in the brain and other tissues. It is highly conserved, with a calculated pI of 11.9 nM and a predicted localization in the cell membrane as a transmembrane protein. PLEKHG3 is involved in a wide range of physiological processes in the brain, including neurotransmitter signaling, synaptic plasticity, and stress response.

One of the most promising aspects of PLEKHG3 is its potential as a drug target. The GPCR family is a common target for drug development, with many FDA-approved drugs, such as beta blockers, neuroleptics, and opioids, belonging to this family. PLEKHG3 is thought to be a potential drug target due to its involvement in neurotransmission and its expression in the brain.

Plekhhg3 has been shown to play a role in neurotransmitter signaling, specifically in the regulation of synaptic plasticity. Synaptic plasticity is the ability of the brain to change and adapt over time, and is thought to be important for learning and memory. PLEKHG3 has been shown to regulate the release of neurotransmitters, such as dopamine and serotonin, and has been shown to play a role in the modulation of synaptic plasticity.

In addition to its role in neurotransmission, PLEKHG3 has also been shown to be involved in stress response. Stress has been shown to play a critical role in the development of various neurological and psychiatric disorders, including anxiety and depression. PLEKHG3 has been shown to be involved in the regulation of stress responses, including the modulation of inflammatory responses and the modulation of cellular signaling pathways involved in stress response.

The potential drug targets for PLEKHG3 are vast and continue to be explored. One possibility is that PLEKHG3 could be used to treat anxiety and depression by modulating neurotransmission and stress responses. Another possibility is that PLEKHG3 could be used to treat neurodegenerative disorders, such as Alzheimer's disease, by modulating neurotransmission and stress responses.

In conclusion, PLEKHG3 is a protein that is expressed in various tissues of the body and is involved in a wide range of physiological processes, including neurotransmission and stress response. Its potential as a drug target is high due to its involvement in these processes and its conservation in the GPCR family. Further research is needed to fully understand the role of PLEKHG3 in disease and to develop effective treatments.

Protein Name: Pleckstrin Homology And RhoGEF Domain Containing G3

Functions: Plays a role in controlling cell polarity and cell motility by selectively binding newly polymerized actin and activating RAC1 and CDC42 to enhance local actin polymerization

The "PLEKHG3 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about PLEKHG3 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets